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Abstract
Background: Despite the diffusion into practice of percutaneous closure of a patent foramen ovale (PFO) in
patients with cryptogenic stroke (CS), the benefits have not been demonstrated, and remain unclear. For any
individual presenting with a PFO in the setting of CS, it is not clear whether the PFO is pathogenically-related to
the index event or an incidental finding. Further, the overall rate of stroke recurrence is low in patients with CS
and PFO. How patient-specific factors affect the likelihood that a discovered PFO is related to an index stroke or
affect the risk of recurrence is not well understood. These probabilities are likely to be important determinants of
the benefits of PFO closure in CS.
Design/Methods: The goal of the Risk of Paradoxical Embolism (RoPE) Study is to develop and test a set of
predictive models that can identify those patients most likely to benefit from preventive treatments for PFO-related
stroke recurrence, such as PFO closure. To do this, we will construct a database of patients with CS, both with and
without PFO, by combining existing cohort studies. We will use this pooled database to identify patient
characteristics associated with the presence (versus the absence) of a PFO, and to use this “PFO propensity” to
estimate the patient-specific probability that a PFO was pathogenically related to the index stroke (Model #1). We
will also develop, among patients with both a CS and a PFO, a predictive model to estimate patient-specific stroke
recurrence risk based on clinical, radiographic and echocardiographic characteristics. (Model #2). We will then
combine Models #1 and #2 into a composite index that can rank patients with CS and PFO by their conditional
probability that their PFO was pathogenically related to the index stroke and the risk of stroke recurrence. Finally,
we will apply this composite index to completed clinical trials (currently on-going) testing endovascular PFO
closure against medical therapy, to stratify patients from low-expected-benefit to high-expected-benefit.
Background
Approximately 40% of all strokes are classified as cryp-
togenic, meaning that the cause is unknown despite an
extensive work up [1]. While patent foramen ovale
(PFO) is a common and generally benign condition
found on autopsy in about 25% of the population [2-4],
approximately 40% to 50% of patients younger than age
5 5w i t hc r y p t o g e n i cs t r o k e( C S )h a v eP F Oo nt r a n s e s o -
phageal echocardiography (TEE) [4-7]. Furthermore, a
PFO is found more frequently in patients with CS than
in patients with a known cause of stroke, even in the
elderly patient[7-9], These association suggest that PFO
has an etiological role in CS, presumably via paradoxical
emboli (PE) (i.e. venous emboli that gain access to the
arterial circulation through a PFO) [7]. Thus, many phy-
sicians will recommend PFO closure in patients, espe-
cially younger patients, who have had CS.
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CS has not been demonstrated, and remains unclear.
First, for a patient presenting with a PFO and a CS, it is
not clear for that individual whether the PFO is causally
related to the index event or whether it is an incidental
finding, since PFOs are so common in the general popu-
lation. Second, the overall rate of stroke recurrence is
relatively low in patients with CS and PFO, ranging in
studies from 0% to 12% per year, with an average
annualized risk across studies of approximately 2%
[4,5,10]. Thus, even rare but serious procedure- and
device-related complications may be sufficient to nullify
the benefit of percutaneous closure, especially if many
who receive the device have index strokes unrelated to
their PFO. A method is needed to identify patients with
CS and pathogenic PFOs, especially those with a high
risk of recurrence from patients with CS and incidental
PFOs.
The theoretical rationale for the RoPE study has been
described in prior work [7,11]. Briefly, the RoPE Study
builds on prior work demonstrating the potential impor-
tance of risk modeling in the interpretation of clinical
trials, where overall results may not reflect the benefits
to individual patients [12-17]. In the setting of CS speci-
fically, we have shown that the probability that an indi-
vidual will have a PFO can be predicted (i.e. prior to
TEE) based on the presence or absence of conventional
stroke risk factors (e.g. age, presence of hypertension,
diabetes, hypercholesterolemia, etc.) and other charac-
teristics. We call the patient-specific probability of find-
ing a PFO in the setting of CS the “PFO propensity”.
Using simple assumptions and Bayes’ theorem, PFO
propensity can be shown to be directly but not linearly
related to the patient-specific PFO-attributable fraction
(i.e. the probability that the PFO is pathogenic rather
than incidental)– as shown in the Figure 1. Thus,
although it is not possible in the individual patient to
determine with certainty whether a discovered PFO is
incidental or pathogenic, it is nonetheless possible to
construct mathematical models that can stratify patients
by their likelihood that their stroke is PFO-related.
Additionally, while prior studies have had limited sta-
tistical power to develop predictive models that can pre-
dict stroke recurrence given the low frequency of this
outcome, the RoPE Study aims to overcome this barrier
by combining multiple large multicentered studies to
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Figure 1 PFO Propensity and the Probability that a Stroke is PFO-attributable. We define PFO propensity as the probability of finding a
PFO in a patient, based on patient-specific characteristics (such as age and the presence or absence of hypertension, diabetes and
hypercholesterolemia). Through Bayes’ theorem, it is directly (though non-linearly) related to the probability that a cryptogenic stroke is PFO-
attributable (in patients with both cryptogenic stroke and PFO).
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brovascular outcome events to model recurrence risk.
The aim of the RoPE Study is to develop mathemati-
cal models that can be used to stratify patients by the
joint probability that an index stroke is “PFO-related”
and that the stroke will recur and to use these models
to stratify patients in on-going clinical trials testing per-
cutaneous closure, with the goal of informing patient-
selection for PFO closure in clinical practice. The steps
by which this will be accomplished are summarized in
Figure 2, as well as in the specific aims below.
Design/Methods
The specific aims of the RoPE Study are:
1. To construct from existing cohort studies of
patients with CS studied with TEE, both with and
without PFO, the largest extant CS database, suffi-
ciently robust to support predictive risk modeling.
2. To identify patient characteristics associated with
the presence (versus the absence) of a PFO, and to
use this “PFO propensity” to estimate the patient-
specific probability that a PFO was pathogenically
related to the index stroke. (Model #1)
3. To develop a predictive model to estimate patient-
specific stroke recurrence risk based on clinical,
radiographic and echocardiographic characteristics
in patients with PFO and CS. (Model #2)
4. To develop a composite index based on Models
#1 & #2 that can rank patients with CS and PFO by
their conditional probability that the PFO was
pathogenically related to the index stroke (Model
#1) and the risk of stroke recurrence (Model #2).
5. To apply this composite index to patients in com-
pleted clinical trials (currently on-going) testing
endovascular PFO closure against medical therapy,
to stratify them from low-expected-benefit to high-
expected-benefit.
Aim 1: To construct the largest extant CS database from
existing cohort studies of patients with CS studied with
TEE for the presence/absence of PFO
Methods for pooling multiple independent studies have
been previously described [18,19]. Steps include: 1)
selection of participating clinical trials and databases; 2)
development of a collaborative investigative team
including clinicians, statisticians and programmers; 3)
preliminary determination of the availability and charac-
teristics of data in each of the component databases; 4)
complete specification of the dependent (outcome) vari-
able used in each study and in the pooled analyses; 5)
determination and specification of the independent
(explanatory) variables; 6) specification of the inclusion/
exclusion criteria for the studies; 7) verification of vari-
able definitions; 8) acquisition of new data if required;
9) checking for consistency of effects across study
databases.
Based on our own literature search, a published litera-
ture review [4], and then subsequently on a published
meta-analysis [10], we contacted all investigators with
relevant data examining the rate of recurrent stroke in
patients CS and PFO. This also yielded data examining
the presence/absence of PFO in patients with CS. We
obtained agreements to include 13 databases with over
2 5 0 0s u b j e c t s ,a ss h o w ni nT a b l e1 .T h i sp r o v i d e st h e
basis of our power calculations for subsequent aims.
Precise determination of inclusion/exclusion criteria,
specification of the independent variables and specifica-
tion of the dependent variable for each of the models
are dependent on careful examination of each of the
component databases for details of variable definition
and missingness. s Consensus on the variables will be
reached among RoPE Investigators for the final models.
Provisional variable descriptions are provided below.
The RoPE Study will include patients with CS who
have been examined for the presence of a PFO with
either TEE or Transcranial Doppler (TCD) and the
injection of bubbles. The preliminary definition of CS
for the RoPE Study conforms to the Trial of ORG
10172 in Acute Stroke Treatment (TOAST) classifica-
tion,[20] and requires a “complete work-up” (defined
below) for the cause of the stroke. Cardioembolic stroke
in this classification was considered “probable” if there
was a high-risk source of embolism and “possible” for
medium risk sources. This latter category includes PFO
and atrial septal aneurysms (ASA). For the purposes of
the RoPE Study, subjects with medium risk sources will
be considered cryptogenic. The definition of stroke for
the RoPE Study is “a sudden onset neurological deficit in
a vascular territory presumed to be due to focal ische-
mia.” If the deficit lasts for less than 24 hours, it must
be accompanied by acute magnetic resonance imaging
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Figure 2 Summary of RoPE Study. Schematic summary of the
Risk of Paradoxical Embolism (RoPE) Study.
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priate locations. If the deficit is greater than 24 hours,
MRI or CT changes are not required. A “complete work-
up” must include: 1) MRI or CT; 2) Vascular imaging -
catheter angiography or angiography by MRI or CT; 3)
Cardiac rhythm study: at least one electrocardiography
(ECG), or documented Holter or telemetry.
In addition to excluding patients with stroke of known
cause, patients included in the RoPE study must be
worked up for the presence of a PFO with a TEE using
intravenous injection of bubbles. Patients can be
included in model #1 without a TEE, if they have had
both transthoracic echocardiography [to rule out other
potential cardioembolic sources] and TCD with bubbles
(to establish the presence/absence of right-to-left shunt-
ing). Only patients with a TEE will be included in
Model #2, since this model will require assessment of
the presence/absence of ASA and PFO grading.
Table 2 shows provisional independent (predictor)
variables that we anticipate will be important in both
the prediction of the presence/absence of PFO, and also
the risk of the outcome (recurrent ischemic stroke, as
defined above). Of note, we anticipate that harmoniza-
tion of databases may require the acquisition of new pri-
mary data, potentially from the following sources: 1)
medical record review 2) rereading of TEE tapes; 3)
rereading of neuroimages; 4) obtaining follow-up for
recurrent events. In general, the reasons for needing
additional primary data from a particular database may
include: 1) missing data on a portion of patients; 2) dif-
fering variable definitions between databases; and 3)
new data (variables) required not previously collected in
a given database. Medical record review would be possi-
ble for clinical registries and TEE tapes and neuroi-
mages are potentially available for most of the
Table 1 RoPE Database
Database # of subjects # w/PFO # w/o PFO RoPE Investigator
APRIS [6] 83 17 66 Marco DiTullio
Bern (published) [30] 159 159 - Krassen Nedeltchev
Bern (unpublished) 249 249 - Heinrich Mattle
CODICIA [31] 486 266 240 Joaquin Serena
PFO-ASA Study [5] 581 267 314 Jean-Louis Mas
German Study [24] 1126 389 737 Christian Weimar
Lausanne 172 93 79 Patrik Michel
NOMASS [32] 60 23 37 Mitchell Elkind
PICSS [33] 250 98 152 Shunichi Homma
Sapienza (unpublished) 343 133 210 Emanuele Di Angelantonio
Federica Papetti
Toronto [34] 114 114 - Cheryl Jaigobin
Tufts 140 140 - David Thaler
Total Estimates* 2546 1484 1062
Table 2 Initial RoPE Variables of Interest
Variable Type Variable
Clinical Age
Gender
Race
History of the following (prior to index stroke)
Migraines
Hypertension
Diabetes
Prior cerebral ischemia
Coronary artery disease
Obesity
Hypercholesterolemia
Smoking status
Antithrombotic medications
Deep vein thrombosis
Pulmonary Embolism
Hypercoagulable states
Antithrombotic medications after index event
Outcome: National Institutes of Health Stroke
Severity Score
Echocardiographic Hypermobility of interatrial septum ("ASA”)
Interatrial shunting at rest (e.g. not during Valsalva
maneuvers)
Volume of interatrial shunt (e.g. max. bubbles in
left atrium)
Anatomical PFO size
Spontaneous Doppler flow seen on color
Radiological MRI/CT findings of cerebral infarct: yes/no (at
index stroke)
Number of prior cerebral infarcts
Anatomical location of index and prior infarct(s)
Kent et al. Trials 2011, 12:185
http://www.trialsjournal.com/content/12/1/185
Page 4 of 9component databases. Based on the characteristics of
any observed missing data we will investigate the use of
imputation and replacement algorithms, or whether a
component database needs to be excluded–although sta-
tistical methods to preserve data and power will be fully
employed (such as imputation for independent vari-
ables). Because missingness of the dependent (outcome)
variable poses more potential problems due to informa-
tive censoring, we intend to exclude any datasets for
which less than 90% of patients have follow-up at one
year. Re-adjudication of all stroke outcomes is planned
as part of the RoPE study. Methods ensuring database
quality during database construction will be comple-
mented by steps taken during the predictive modeling
process to check for consistency of effects across
databases.
Aim 2: To identify patient characteristics associated with
the presence (versus the absence) of a PFO, and to use
this “PFO propensity” to estimate the patient-specific
probability that a PFO was pathogenically related to the
index stroke. (Model #1)
Since PFOs discovered in patients with CS may be
pathogenically related to the stroke or not, in Aim 2, we
will use logistic regression models to identify patient
characteristics that are associated with the presence of a
PFO among patients with CS ("PFO propensity”). In
previous work [7,11,21], we have shown that this “PFO
propensity” can be related to the probability that a PFO
is pathogenic (i.e. non-incidental) using Bayes’ theorem
and 2 simple assumptions: 1) if not for those strokes
that are PFO-attributable, the probability of a PFO in a
CS patient would be the same as in the general popula-
tion (controls); and 2) the rate of PFO-attributable
strokes in PFO-negative CS patients is near-zero. Under
these conditions:
Probability that PFO is incidental in a CS case =
PFO probability in controls ∗ (1 − Probability of PFO in CS case)
Probability of PFO in CS case ∗ (1 − PFO probability in controls)
Since the patient-specific probability of PFO in CS is
g i v e nb yt h eP F Op r o p e n s i t y( i . e .t h ep r e v a l e n c eo fP F O
in CS patients otherwise similar to the patient), the only
additional term needed to estimate the probability that a
PFO is incidental for a particular patient is the general
rate of PFO in the population (PFO probability in
controls).
To develop a predictive model for PFO propensity, we
will explore crude associations (overall and within each
database) between the presence of a PFO and clinical
variables including the subject’s age, gender, race, hyper-
tension, diabetes, hyperlipidemia, history of prior epi-
sodes of cerebral ischemia, obesity, antithrombotic
medications, concurrent deep venous thrombosis, and
neuroradiologic variables (i.e. prior stroke on MRI or
CT, small [< 1.5 cm] versus large infarct, location of
infarct). Multivariable associations between predictors
and the presence of a PFO will be examined using logis-
tic regression models. Selection of candidate variables
for these models will be based on clinical rationale and
the published literature. Variables with statistically mar-
ginal associations in the preliminary analyses (p > 0.15)
will be removed. Non-linear associations between inde-
pendent risk variables and the outcome will be investi-
gated using generalized additive spline models[22]. As
indicated, appropriate parametric logistic regression
models will be developed to capture these non-linear
relationships.
Statistical significance of individual variables in the
final model will be assessed with the Score statistic.
Based on clinical reasoning, a limited number of interac-
tion terms between risk factors may also be tested for
inclusion in the model. The models will be analyzed by
conventional criteria, such as goodness-of-fit tests, and
receiver operator characteristics (ROC) curve areas [23].
“Calibration” of predicted probabilities of outcome
throughout the range of their predictions will be evalu-
ated with plots. The final multivariable regression mod-
els will be run separately on each of the component
datasets to assess the consistency of the results and
model performance. Based on these results, interaction
terms between indicator variables representing study
and model predictors of PFO will be used to investigate
significant variation in associations across study datasets.
Predictors found to be inconsistent across studies may
be removed from the model. We will reanalyze the data
using a generalized linear mixed model that includes a
random effect term for study to get final parameter esti-
mates with their corresponding standard errors.
Adequacy of the Data for Aim 2: Based on a prelimin-
ary review of the included studies (see Table 1), we will
have potentially 3,101 subjects available for the models
predicting PFO (1,332 with and 1,769 without PFOs),
drawn only from those databases enrolling all crypto-
g e n i cs t r o k ep a t i e n t sw i t ha n dw i t h o u tP F O .T h i ss a m -
ple size will provide 80% power to detect an odds ratio
of 1.23 for a balanced risk factor. For a risk factor with
ap r e v a l e n c eo f2 0 % ,t h i ss a m p l es i z ew i l ls t i l lp r o v i d e
80% power to detect an odds ratio of 1.29. The study
will still provide sufficient power to detect clinically
relevant associations even in the presence of significant
data being unavailable for modeling. For example, if we
totally eliminate data from the largest RoPE component
study (the German database [24]), we will have 1,975
included subjects (928 with and 1047 without PFOs.)
This sample will provide 80% power to detect odds
ratios of 1.29 and 1.38 for risk factors with a prevalence
of 0.50 and 0.20, respectively. Since outcome data is not
needed for this analysis, loss of this amount of data is
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power, permitting full exploration of multiple variables.
Aim 3. To develop a predictive model to estimate
patient-specific recurrence risk based on clinical,
radiographic and echocardiographic characteristics in
patients with PFO and CS. (Model #2)
For Aim 3 we will use Cox proportional hazard models
to develop a predictive model to estimate patient-speci-
fic recurrence risk. Because patients with CS with higher
PFO-related recurrence risk generally have a lower pre-
valence of conventional stroke risk factors[25], failure to
adjust for general (non-PFO-related) recurrent risk can
lead to paradoxical results. This has been a major chal-
lenge for prior studies, since the low rate of outcomes
limits the statistical power to control for conventional
stroke risk factors and model PFO-related risk. While in
the RoPE study we will have many-fold the number of
outcomes compared to any prior study, statistical power
for this analysis remains an issue.
To address this, depending in part on the number of
outcomes, we will consider a two-step approach, that
takes advantage of the outcomes in the component of
the RoPE database of CS patients without PFO. First, we
will construct a model for recurrence risk on the com-
ponent of the study of CS patients without PFO. Next,
we will construct a model for recurrence risk on the
component of the study of CS patients with PFO, using
the derived risk variable from the first step to control
for the confounding background risk of stroke from
PFO-unrelated causes. This will permit background
stroke risk to be controlled for in a statistically efficient
fashion. For step two, using the study subjects with
known PFO, we will pay particular attention to echocar-
diographic information (e.g. hypermobility of the intera-
trial septum, interatrial shunting at rest, severity of
interatrial shunt, anatomical PFO size, presence/absence
of spontaneous flow on color Doppler)–to identify fea-
tures of “high-risk” PFOs.
Preliminary analyses for both phases of this two step
process (i.e. modeling recurrence risk in patients with-
out PFO and modeling recurrence risk in patients with
PFO) will investigate associations between established
risk factors and recurrent strokes. Kaplan-Meier survival
curves and logrank tests will be used to assess statistical
significance. For each phase, a multivariable prediction
model for recurrent stroke will be developed using a
Cox proportional hazard model, using an approach
otherwise similar to that described for Aim 2. Predictive
discrimination will be assessed using the overall C index
[26]. Model calibration is assessed by comparing pre-
dicted survival probabilities against Kaplan-Meier
(observed) probabilities across equal-sized risk quantiles
(based on predicted recurrence probabilities).
Differences between predicted and observed probabil-
ities will be compared using a modified Hosmer-Leme-
show c
2 statistic [27]. The Cox models be re-run
including the study as a stratification factor to control
for potential between-study differences in baseline survi-
val functions when estimating hazard ratios of potential
risk factors.
Adequacy of the data for Aim 3: Power was calculated
on extreme optimistic and extreme pessimistic calcula-
tions. To obtain outcome rates for our sample we used
databases with patients who had PFOs. We optimisti-
cally estimate available follow-up data for up to 1,752
patients with PFO; 1,332 from databases with both PFO
and non-PFO patients and an additional 420 from data-
bases that only have data on patients with PFOs. Based
on the average outcome rates on the observed data, the
estimated stroke rate for these patients is 6%. The sam-
ple size of 1,752 will provide 80% power to detect a
clinically relevant hazard rat i oo f1 . 7 7f o rar i s kf a c t o r
with a prevalence of 50% and an overall stroke rate of
6%. Most pessimistically, wee x c l u d e d1 0 0 %o fo u rl a r -
gest study (the German study [24]) and estimated fol-
low-up will only be available for 70% of the remaining
subjects which would result in a total sample size of
944. With this extremely conservative estimate of the
sample size the study will have 80% power to detect a
hazard ratio of 2.22 assuming an overall stroke rate of
6% and a risk factor prevalence of 50%.
While having a sample size toward this lower estimate
would still be adequate to detect these moderate to
large effects, it would require us to be parsimonious in
testing variables to avoid over-fitting (only about 60
stroke outcomes in PFO patients). After final database
construction, we will consider whether to model the risk
of the composite outcome stroke and transient ischemic
attack (TIA). This has an outcome rate of 11.2% on the
sample of our database with completed follow-up, vir-
tually doubling the number of outcomes.
Aim 4. To develop a composite index that can rank
patients with CS and PFO by their conditional probability
that the PFO was pathogenically-related to the index
stroke (Model #1) and the risk of stroke recurrence
(Model #2)
For Aim 4, we will combine our probability models in
order to stratify patients by their risk of stroke recur-
rence conditioned on the probability that the PFO is
pathogenically-related (i.e. not incidental) to the index
stroke. Thus, the aim of this step is to combine models
to estimate the PFO-attributable recurrence risk. This
step prepares us for Aim 5: stratification of the clinical
trial populations by this attributable recurrence risk,
which we hypothesize corresponds to stratification by
expected-benefit. In performing Aim 5, it is important
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positive results due to multiple comparisons. Indeed, an
advantage of multivariable risk-based analysis is that it
allows the influence of multiple variables to be summar-
ized along a single dimension and thus minimize the
risks of this Type I error. However, this is only the case
if the stratification is fully specified, before the outcomes
are examined, since even with a single risk model minor
differences in stratification can influence results; when
two risk models are combined, the potential for analytic
flexibility-and therefore bias–is increased. While this
Aim needs to be informed by the results of Aims 2 and
3, and the observed risk distributions in the RoPE popu-
lations, to emphasize the importance of full pre-specifi-
cation of the stratification strategy, process and analysis
before the outcome data of the randomized controlled
trials (RCTs) are examined, we have partitioned this
into a separate specific aim, to be completed before Aim
5.
A challenge of this step is that transformation of PFO
propensity into a probability that a PFO is pathogenic
versus incidental requires an estimate of the rate of PFO
in a control population. The control rates of TEE-
detected PFOs vary somewhat from study to study, pre-
sumably due to variation in TEE technique (since the
presence of a PFO rates have been shown to be largely
independent of patient characteristics in unselected
[screened] populations[25,28]. Figure 1 shows the rela-
tionship of PFO propensity to the probability that a
PFO is pathogenic under the assumptions that the con-
trol PFO rate is 15%, 20% and 25%. While the ranking
of patients according to their probability that their PFO
is pathogenically related to their index event is insensi-
tive to the exact control rate selected, to converge on a
control rate that would allow us to combine models #1
and #2, we will: 1) perform meta-analysis of control
groups in prior case-control studies (CS versus non-
cryptogenic stroke patients); 2) analyze the PFO-rate in
TEE-studied non-cryptogenic stroke patients in compo-
nent RoPE studies that included such patients (such as
PICSS, which has 365 TEE-studied non-cryptogenic
stroke patients). We will explore the distribution of the
patient-specific probability that the discovered PFO is
pathogenic across the different strata of the RoPE
population.
Once the models are combined to produce the prob-
ability of stroke recurrence conditional on the probabil-
ity that the index event was PFO-related (i.e. PFO-
attributable recurrence risk), and based on a thorough
understanding of the risk profile of the patients in the
RoPE population and the randomized clinical trial popu-
lation (but prior to any analysis of outcomes in the
RCTs), the full stratification plan will be specified, as
provisionally outlined in Aim 5.
Aim 5: To apply this score to patients in completed
clinical trials (currently on-going) testing percutaneous
PFO closure against medical therapy, from low-expected-
benefit to high-expected-benefit
The primary hypothesis of Aim 5 is that there will be a
treatment-by-index interaction, when patients enrolled
in RCTs testing PFO closure are ranked by their risk of
stroke recurrence, conditioned on the probability that
the PFO was pathogenically-related to the index event
(using the composite index as a continuous variable). A
p - v a l u eo f0 . 0 5w i l lb et h et h r e s h o l df o rs i g n i f i c a n c e .
Depending on results, a clinically usable model will be
developed. This step comprises external validation of
the combined model. In addition, model 2 (the CS
recurrence risk model) will be externally validated on
the pooled medical arms of the RCTs by conventional
criteria, including goodness-of-fit tests, ROC curve areas
and calibration plots as described in the prior aims.
For Aim 5, we have, as of this writing, received agree-
ment to test the risk models on two RCT databases,
which will be pooled. Additional RCTs will be sought.
The two RCTs to be pooled are:
Randomized Evaluation of Recurrent Stroke compar-
ing PFO Closure to Established Current Standard of
Care Treatment (RESPECT) Trial: (http://ClinicalTrials.
gov identifier: NCT00465270) This is a prospective, ran-
domized, multi-center trial, enrolling at 60 North Amer-
ican centers, designed to investigate whether
percutaneous PFO closure with the Amplatzer PFO
Occluder is superior to current standard of care medical
treatment in the prevention of recurrent stroke. Inclu-
sion criteria include age of 18-60 years old, cryptogenic
stroke (not TIA) within 270 days, and TEE demonstra-
tion of a PFO. The recruitment target is 1000 subjects
who will be randomized 1:1 to endovascular PFO clo-
sure or medical management. The primary endpoints
are recurrence of non-fatal stroke, post-randomization
death, and fatal ischemic stroke.
PC-Trial: Patent Foramen Ovale and Cryptogenic
Embolism: (ClinicalTrials.gov identifier: NCT00166257).
The PC-Trial is very similar in design to the RESPECT
Trial comparing the efficacy of percutaneous PFO clo-
sure with medical treatment in 26 European centers. An
additional inclusion criterion is cryptogenic peripheral
embolism. Subjects are being stratified according to age
and presence or absence of an atrial septal aneurysm.
The recruitment target is 410 and the primary outcome
is death, non-fatal stroke and peripheral embolism[29].
Adequacy of the Data for Aim 5: The proposed sam-
ple of 1400 subjects from RESPECT and the PC-Trial
will provide sufficient power to detect a moderate inter-
action in the association of the recurrent risk stratifica-
tion and the two study treatment groups. Power was
estimated through simulations in SAS across multiple
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Page 7 of 9parameter configurations. For example, the proposed
study sample of 700 subjects in each study arm, with an
overall recurrence rate of 5% (stroke only), will provide
approximately 80% power to detect a difference in the
hazard ratio for a change of 10% in predicted risk of
1.00 and 1.33 for the two study groups, assuming a uni-
form distribution of risk scores. Additional RCTs will
also be sought.
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